Inj. Magnesii Sulfurici Polpharma (Magnesium Sulfate)

Magnesium sulfate releases magnesium ions that serve as cofactors for many enzymes, stabilise cell membranes, and antagonise calcium at voltage‑gated channels. This results in vasodilation, reduced neuromuscular excitability, and normalisation of cardiac electrical activity, helping to correct deficiencies and prevent seizures.

The specific dose of Inj. Magnesii Sulfurici Polpharma is determined by the prescribing clinician based on the patient’s condition, weight, renal function and therapeutic goals. Healthcare professionals calculate the appropriate amount and administration rate for each individual case.

Magnesium sulfate is commonly used in obstetric emergencies such as eclampsia, where the benefits outweigh potential risks. However, its use during pregnancy or lactation should be guided by a qualified healthcare provider who will assess maternal and fetal safety.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and necessary import documentation.

Inj. Magnesii Sulfurici Polpharma is an injectable magnesium sulfate formulation, offering rapid systemic availability compared with oral magnesium salts, which have slower absorption and variable bioavailability. It is preferred in acute settings such as severe deficiency, obstetric emergencies, or life‑threatening arrhythmias where immediate therapeutic levels are needed.

The product should be stored at 2‑8 °C, kept refrigerated, protected from light, and must not be frozen or shaken. Before use, inspect the vial for particulate matter or discoloration and allow it to reach room temperature if required for administration.

It is administered by a qualified healthcare professional via intramuscular or intravenous injection. The route, infusion rate and dilution (if any) are determined by the prescriber according to the clinical indication, patient condition and institutional protocols.

Serious risks include severe hypotension, life‑threatening arrhythmias, respiratory depression, hypermagnesemia leading to neuromuscular weakness or cardiac arrest, and rare anaphylactic reactions. Prompt monitoring of vital signs and serum magnesium levels helps mitigate these hazards.

Patients with known hypersensitivity to magnesium sulfate, severe renal impairment without appropriate monitoring, or those with existing hypermagnesemia should avoid this medication. Clinicians must also exercise caution in individuals with heart block, myasthenia gravis or concurrent use of potent neuromuscular blockers.